Document Detail


Inotropes in cardiac patients: update 2011.
MedLine Citation:
PMID:  20711077     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: ICU patients frequently develop low output syndromes due to cardiac dysfunction, myocardial injury, and inflammatory activation. Conventional inotropic agents seem to be useful in restoring hemodynamic parameters and improving peripheral organ perfusion, but can increase short-term and long-term mortality in these patients. Novel inotropes may be promising in the management of ICU patients, having no serious adverse effects. This review summarizes all the current knowledge about the use of conventional and new inotropic agents in various clinical entities of critically ill patients.
RECENT FINDINGS: In recent European Society of Cardiology guidelines, inotropic agents are administered in patients with low output syndrome due to impaired cardiac contractility, and signs and symptoms of congestion. The most recommended inotropes in this condition are levosimendan and dobutamine (both class of recommendation: IIa, level of evidence: B). Recent data indicate that levosimendan may be useful in postmyocardial infarction cardiac dysfunction and septic shock through increasing coronary flow and attenuating inflammatory activation, respectively. Furthermore, calcium sensitizing by levosimendan can be effectively used for weaning of mechanical ventilation in postcardiac surgery patients and has also cardioprotective effect as expressed by the absence of troponin release in this patient population. Finally, new agents, such as istaroxime and cardiac myosin activators may be safe and improve central hemodynamics in experimental models of heart failure and heart failure patients in phase II clinical trials; however, large-scale randomized clinical trials are required.
SUMMARY: In an acute cardiac care setting, short-term use of inotropic agents is crucial for the restoration of arterial blood pressure and peripheral tissue perfusion, as well as weaning of cardiosurgery. New promising agents should be tested in randomized clinical trials.
Authors:
John T Parissis; Pinelopi Rafouli-Stergiou; Vassilios Stasinos; Panagiotis Psarogiannakopoulos; Alexandre Mebazaa
Related Documents :
25242157 - The thebesian valve and its significance for electrophysiologists.
16333237 - Acute decompensated heart failure: best evidence and current practice.
20843567 - Safety and efficiency of chronic ace inhibition in symptomatic heart failure patients w...
2014917 - Importance of raa system and the treatment of patients with ace inhibition after myocar...
23394547 - Intracoronary injection of glycoprotein iib/iiia, abciximab, as adjuvant therapy in pri...
15249807 - Syncope in acute pulmonary embolism.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in critical care     Volume:  16     ISSN:  1531-7072     ISO Abbreviation:  Curr Opin Crit Care     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-09     Completed Date:  2011-01-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9504454     Medline TA:  Curr Opin Crit Care     Country:  United States    
Other Details:
Languages:  eng     Pagination:  432-41     Citation Subset:  IM    
Affiliation:
Heart Failure Unit, Attikon University Hospital, Athens, Greece. jparissis@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiotonic Agents / therapeutic use*
Critical Illness / therapy*
Humans
Chemical
Reg. No./Substance:
0/Cardiotonic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Continuum of hospital care: the role of intensive care.
Next Document:  Prophylaxis, empirical and preemptive treatment of invasive candidiasis.